AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05682118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: roadmap
Description: FFR and iFR tests using the roadmap system, or FFR and iFR tests without using the roadmap system.~Pressure wire into guiding catheter The equalization of the pressure wire with the aortic pressure(after placing the pressure wire on the tip of the guiding catheter and removal of contrast media by saline flushing) and the placement of the pressure wire on the distal of the blood vessel to measure iFR. After iFR measurement, the pressure wire was pulled back into the tip of the guiding catheter to check the presence of pressure drift. A final Pd/Pa between 0.97 and 1.03 is considered acceptable. Following confirming no pressure drift, a mode change will be done from iFR to FFR, and then a re-check of the time between the equalization of the pressure wire with the aortic pressure will be planned. In all lesions, FFR value were measured with hyperemia, achieved by intracoronary (IC) bolus injection of nicorandil (Sigmart®; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) 2 mg.
Study NCT05682118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iFR/FFR
Description: Patients undergoing pressure wire test with moderate stenosis. Pressure wire into guiding catheter The equalization of the pressure wire with the aortic pressure(after placing the pressure wire on the tip of the guiding catheter and removal of contrast media by saline flushing) and the placement of the pressure wire on the distal of the blood vessel to measure iFR. After iFR measurement, the pressure wire was pulled back into the tip of the guiding catheter to check the presence of pressure drift. A final Pd/Pa between 0.97 and 1.03 is considered acceptable. Following confirming no pressure drift, a mode change will be done from iFR to FFR, and then a re-check of the time between the equalization of the pressure wire with the aortic pressure will be planned. In all lesions, FFR value were measured with hyperemia, achieved by intracoronary (IC) bolus injection of nicorandil (Sigmart®; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) 2 mg.
Study NCT05682118 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: iFR/FFR
Description: Patients undergoing pressure wire test with moderate stenosis. Pressure wire into guiding catheter The equalization of the pressure wire with the aortic pressure(after placing the pressure wire on the tip of the guiding catheter and removal of contrast media by saline flushing) and the placement of the pressure wire on the distal of the blood vessel to measure iFR. After iFR measurement, the pressure wire was pulled back into the tip of the guiding catheter to check the presence of pressure drift. A final Pd/Pa between 0.97 and 1.03 is considered acceptable. Following confirming no pressure drift, a mode change will be done from iFR to FFR, and then a re-check of the time between the equalization of the pressure wire with the aortic pressure will be planned. In all lesions, FFR value were measured with hyperemia, achieved by intracoronary (IC) bolus injection of nicorandil (Sigmart®; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) 2 mg.
Study NCT06316921 — intervention group
Intervention type: PROCEDURE
Intervention: Epidural patient-controlled analgesia
Description: Epidural patient-controlled analgesia for postoperative pain after lumber spine surgery
Study NCT06316921 — intervention group
Intervention type: PROCEDURE
Intervention: Standard postoperative pain management
Description: Standard of care for postoperative pain after lumber spine surgery
Study NCT05991726 — intervention group
Intervention type: OTHER
Intervention: Other: Survey
Description: Multiple survey rounds identifying most important outcomes for effective self-management for non-dialysis CKD
Study NCT05701670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Purrble+SSI
Description: Purrble intervention as described above.~Single Session Intervention (SSI) (\~30mins) combining the theories of ER with the experiences from students involved in previous studies, and follows a traditional SSI structure (Schleider et al 2020). Specific content has been co-produced with students and experts.
Study NCT06032793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: Pursed lip breathing, Diaphragmatic breathing and powered breathing
Study NCT05407025 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood, urine, and tissue samples
Study NCT05407025 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete risk factor questionnaire
Study NCT05607420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCART20x22
Description: Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptors given following a lymphodepletion regimen
Study NCT05607420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLLS52
Description: A monoclonal antibody that recognizes a CD52 antigen
Study NCT06328010 — intervention group
Intervention type: BIOLOGICAL
Intervention: Advanced Treatment Modalities for wound and injuries
Description: Synthetic, Amniotic, Bovine, Porcine, or other non-human biological grafts or scaffolded grafts
Study NCT06328010 — intervention group
Intervention type: BIOLOGICAL
Intervention: Standard of care
Description: Standard of care without use of grafts or scaffolded grafts
Study NCT06328010 — intervention group
Intervention type: OTHER
Intervention: Retrospective wound treatment data collection
Description: Completed wound care treatment regardless of modality.
Study NCT04771208 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: I kua na'u Let Me Carry Out Your Last Wishes
Description: A combination of Native Hawaiian advance care planning video decision support tool and personalized video declarations shared with providers and family members.
Study NCT04771208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I kua na'u Let Me Carry Out Your Last Wishes
Description: A combination of Native Hawaiian advance care planning video decision support tool and personalized video declarations shared with providers and family members.
Study NCT06641154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT-UGT1A1-AAV8-02
Description: Intravenous infusion, single dose
Study NCT06644625 — intervention group
Intervention type: OTHER
Intervention: Blood draw for the laboratory assessment
Description: Screening blood sample collection to test for MGUS
Study NCT05820685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Participants in this arm will get acetaminophen 1000 mg every six hours, naproxen 500 mg every 12 hours, gabapentin 300 mg every eight hours, and Tramadol 50 mg every six hours as needed for breakthrough pain
Study NCT05820685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Participants in this arm will get acetaminophen 1000 mg every six hours, naproxen 500 mg every 12 hours, gabapentin 300 mg every eight hours, and Tramadol 50 mg every six hours as needed for breakthrough pain
Study NCT05820685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Participants in this arm will get Dronabinol 10 mg in addition to standard of care pain medication as needed for breakthrough pain
Study NCT05602064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen is a non-steroidal anti-inflammatory drug which acts by reducing the production of cyclo-oxygenases (COX-1 and COX-2)- derived prostanoids in the blood
Study NCT05602064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol is an analgesic that acts peripherally; although its primary site of action is still debatable, it is thought to inhibit prostaglandins in the hypothalamus
Study NCT05602064 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo solution will be freshly prepared by an assistant in a manner to match the color and odor of the analgesics
Study NCT04671888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: COPD patients will be asked to wear a data logger system to collect EMG data and respiration parameters during exercise that simulate daily activity (i.e., walking, cycling)
Study NCT05290194 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT radiotherapy + Conventionally fractionated radiotherapy
Description: Radiotherapy was performed 3-6 weeks after the end of first-line treatment, followed by conventional fractionated radiotherapy of the primary tumor and cervical lymph node metastases, SBRT radiotherapy of distant organ metastases 3-6 weeks later.
Study NCT05290194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Immunotherapy of PD-1 inhibitor is used during the whole time of this trial until subjects were withdrawn from the trial or the trial complete
Study NCT05290194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is treated for patients 3-6 weeks after radiotherapy, which combines with PD-1 inhibitor as the maintenance regimen in the trial.
Study NCT05427383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026/Placbo Injection
Description: IV KN026/Placebo at 30 mg/kg on D1, Q3W
Study NCT05427383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Injection
Description: IV Paclitaxel at 175 mg/m² on D1, Q3W
Study NCT05427383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel Injection
Description: IV Docetaxel at 75 mg/m² on D1, Q3W
Study NCT05427383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Injection
Description: IV Irinotecan at 125 mg/m² on D1, D8, Q3W
Study NCT05989893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language-based tasks
Description: In either the MRI suite, or the Epilepsy Monitoring Unit, or the operating room, epilepsy and tumor subjects are asked to perform a variety of language-based tasks as neural recordings are made from and/or neural stimulations are delivered to various language areas of the brain.
Study NCT06295653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant placement and soft tissue augmentation with Autogenous Subepithelial Connective Tissue Graft or Amniotic Chorion Membrane
Description: assess the efficacy of the peri-implant mucosal thickness enhancement following either subepithelial connective tissue grafts or Amniotic Chorion Membrane placed simultaneously with dental implant placement.
Study NCT05948618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Embodied Conversational Agent
Description: The ECA- PRO measures will included PROMIS Profile measures, which include depression, anxiety, fatigue, pain intensity, and interference, fatigue, sleep disturbance, physical function, and satisfaction with social roles. In order to reduce boredom and confusion, equivalent forms of different items will be selected from the items pools. In this way, participants are not answering the same questions twice within one session.
Study NCT05948618 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: REDCap Survey
Description: An internet-based measure will use PROMIS Profile measures which will include depression, anxiety, fatigue, pain intensity and interference, sleep disturbance, physical function and satisfaction with social role
Study NCT06422143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion
Study NCT06422143 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion
Study NCT06422143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sac-TMT
Description: IV infusion
Study NCT05215353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Participants will receive seven weekly 60-minute treatments of music therapy. All sessions will be delivered virtually through Zoom.
Study NCT05215353 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Participants will receive seven weekly 60-minute treatment of cognitive behavioral therapy. All sessions will be delivered virtually through Zoom.
Study NCT05215353 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: assessments
Description: Participants will complete study assessments prior to randomization (week 0) and at weeks 4, 8, 16, and 26. A subgroup of 60 survivors will complete optional semi-structured interviews after treatment to understand their unique experiences with MT or CBT. All participants will be followed for 26 weeks.
Study NCT05215353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assessments
Description: Participants will complete study assessments prior to randomization (week 0) and at weeks 4, 8, 16, and 26. A subgroup of 60 survivors will complete optional semi-structured interviews after treatment to understand their unique experiences with MT or CBT. All participants will be followed for 26 weeks.
Study NCT05847166 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: [99mTc]Tc-PSMA-T4
Description: \[99mTc\]Tc-PSMA-T4 for intravenous administration. The investigational medicinal product is to be prepared directly in a clinic by radiolabeling the radiopharmaceutical kit containing PSMA-T4 as a drug substance with sodium pertechnetate (99mTc) injection. The \[99mTc\]Tc-PSMA-T4 radiopharmaceutical should be used for targeted radionuclide SPECT imaging in patients with tumors and metastases of prostate cancer. The investigational medicinal product \[99mTc\]Tc-PSMA-T4 is dedicated for intravenous administration in radioactivity dose (555 - 740 MBq in cohorts A, B, C.
Study NCT05890001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI5100
Description: Patients will take BLI5100 once daily, orally, for up to 29 weeks.
Study NCT06171685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teclistamab Monotherapy
Description: standard of care
Study NCT06171685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: investigational doses compared to SOC
Study NCT05838313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elective Induction of Labor Decision Support Tool
Description: Decision support tool for people having their first baby and planning vaginal delivery without a medical indication for induction of labor
Study NCT05723653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project nGage
Description: Project nGage (nGage) is an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among young Black sexual minority men. The nGage intervention consists of (1) selection and invitation of a Support Confidant (SC), (2) a face-to-face intervention between the Intervention Case Manager and the Index and SC, and (3) quarterly interactive mini-booster sessions delivered to the Index and SC via text or telephone, based on participant preference.
Study NCT05962489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinically optimized deep brain stimulation
Description: Participants will have DBS implanted as standard-of-care. We will be examining the effects of their regular clinical stimulation settings versus no stimulation.
Study NCT05447663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siremadlin
Description: Siremadlin was administered at a starting dose of 30 mg/day on days 1-5 of a 28-day treatment cycle (Part 1).
Study NCT05348733 — intervention group
Intervention type: DRUG
Intervention: Kerendia (Finerenone, BAY94-8862)
Description: Decision will taken by the treating physician to initiate treatment with finerenone.
Study NCT05427123 — intervention group
Intervention type: OTHER
Intervention: Medication or psychosocial treatment
Description: Youth included in this naturalistic study will be offered medication management from study psychiatrists. The study's Network Oversight Committee, consisting of PI psychiatrists and consultants, has created guidelines on best practice medications, dosing, and adjustments for the study. The Network Oversight Committee will also offer ongoing consultation to study psychiatrists. The treating physician will take these guidelines and recommendations under consideration but will use clinical judgment and have the final say, in consultation with the parents and child, as to what treatments are prescribed. While psychosocial interventions are of interest as a predictor of outcomes, no universal psychotherapy or other psychosocial treatment will be provided by sites. There is no limitation on participant enrollment in psychosocial treatments. Investigators and their clinical partners may offer these interventions based on clinical judgment and availability.
Study NCT05589389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Healthy Eating Index Diet with Minimally Processed Meat
Description: Participants will consume a diet with a high Healthy Eating Index along with meat that is minimally processed.
Study NCT05589389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Healthy Eating Index Diet with Further Processed Meat
Description: Participants will consume a diet with a high Healthy Eating Index along with meat that is further processed.
Study NCT05589389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Typical Healthy Eating Index Diet with Minimally Processed Meat
Description: Participants will consume a diet with a typical Healthy Eating Index along with meat that is minimally processed.
Study NCT05589389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Typical Healthy Eating Index Diet with Further Processed Meat
Description: Participants will consume a diet with a typical Healthy Eating Index along with meat that is further processed.
Study NCT06454812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical vibration
Description: The vibration device will be placed on the procedure site (on the vastus lateralis muscle) on the left extremity and fixed through a long gauze. The vibration device will be operated for 30 seconds with reference to previous studies, then the nurse will administer routine intramuscular Hepatitis B vaccine. A gap of approximately 1-2 cm will be left between the device and the injection site. After the vaccination procedure is completed, the vibration will be terminated. The same procedure was repeated for DTaP-IPV-Hib vaccine administered to the the right extremity. The baby will be swaddled and placed in the mother's lap.
Study NCT06454812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helfer skin tap technique (HSTT)
Description: In this group, HSTT consisting of 4-stage strokes will be applied to the vaccination site. The nurse will make approximately 10 strokes for 5 seconds with the palmar side of the fingers of the dominant hand to the injection site to relax the muscles (Stage 1). The nurse will give a V-shaped position to the thumb and index finger of the non-dominant hand and give 3 strokes to the injection site with the palmar side of the fingers (Stage 2). The skin entry site of the needle will remain inside the V-shape. Simultaneously with the 3rd stroke, the nurse will insert the needle into the muscle at a 90 degree angle. The nurse will inject the vaccine into the muscle while continuing to tap the skin with the palmar side of the fingers of the non-dominant hand (Stage 3). The nurse will make 3 strokes on the skin with the palmar side of the fingers of the non-dominant hand at the injection site, simultaneously with the 3rd stroke, the needle will be removed from the baby's skin (Stage 4).
Study NCT05100342 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Point score prediction tool for 30-day survival
Description: This tool requires laboratory data including white blood cell count, neutrophil-lymphocyte ratio, blood urea nitrogen, bilirubin, albumin, lactate dehydrogenase, and red cell distribution, as well as number of attendances to the emergency room in the past 100 days, the site receiving radiation therapy, and the primary cancer type. Each data point correlates with a point value, which are tallied to generate a final score.~The scores range from 0-20, with 0 giving the highest chance for survival at 30 days and 20 giving the lowest chance for survival at 30 days
Study NCT06356311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: Participants will receive sacituzumab tirumotecan as 4mg/kg IV infusion on days 1, 15, and 29 of every 42-day cycle.
Study NCT06356311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trifluridine-Tipiracil
Description: Trifluridine-tipiracil will be administered at 35 mg/m\^2 as tablet orally twice a day on days 1-5 and 8-12 of every 28-day cycle.
Study NCT06356311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan will be administered at a dose of 150 mg/m\^2 by IV infusion on days 1 and 15 of every 28-day cycle.
Study NCT06356311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 80 mg/m\^2 by IV infusion on days 1, 8 and 15 of every 28-day cycle.
Study NCT06356311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be administered at a dose of 75 mg/m\^2 by IV infusion on day 1 of a 21-day cycle.
Study NCT06356311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Participants are allowed to take rescue medication for stomatitis or oral mucositis. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion or steroid mouthwash (dexamethasone or equivalent), antiemetic medications, oral nystatin suspension or antifungal medications, antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.